Laura Chico
Stock Analyst at Wedbush
(1.98)
# 2,871
Out of 4,829 analysts
214
Total ratings
33.33%
Success rate
-8.42%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Outperform | $32 → $30 | $14.37 | +108.77% | 8 | May 7, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $34 → $26 | $21.71 | +19.76% | 8 | May 7, 2025 | |
| JBIO Jade Biosciences | Initiates: Outperform | $17 | $8.65 | +96.53% | 1 | May 7, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $26 → $28 | $38.35 | -26.99% | 7 | May 5, 2025 | |
| VIGL Vigil Neuroscience | Reiterates: Outperform | $13 | $2.46 | +428.46% | 10 | May 5, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $30 | $20.02 | +49.85% | 10 | May 2, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $43 | $14.58 | +194.92% | 10 | Apr 21, 2025 | |
| TRML Tourmaline Bio | Maintains: Outperform | $42 → $43 | $15.10 | +184.77% | 2 | Mar 14, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.11 | +260.36% | 4 | Mar 14, 2025 | |
| OVID Ovid Therapeutics | Maintains: Outperform | $4 → $3 | $0.29 | +934.13% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $19.61 | +83.58% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $4.23 | +561.94% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $17.30 | +67.63% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $6.57 | -8.68% | 9 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $147 | $115.71 | +27.04% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 → $48 | $35.11 | +36.71% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.76 | +479.71% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.50 | +702.68% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $4 | $2.22 | +80.18% | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.12 | +937.74% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $118.17 | +73.48% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $35.02 | +39.92% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.17 | +120.82% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.62 | +203.87% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $12.39 | +238.98% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $9.36 | +81.62% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $16.60 | +86.75% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.29 | +3,654.27% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $3.50 | +42.86% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.86 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.13 | +134.74% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $20.24 | +633.70% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $6.45 | +11,062.79% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $18.63 | +1,402.95% | 1 | Apr 21, 2017 |
Denali Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.37
Upside: +108.77%
Vera Therapeutics
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $21.71
Upside: +19.76%
Jade Biosciences
May 7, 2025
Initiates: Outperform
Price Target: $17
Current: $8.65
Upside: +96.53%
Praxis Precision Medicines
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $38.35
Upside: -26.99%
Vigil Neuroscience
May 5, 2025
Reiterates: Outperform
Price Target: $13
Current: $2.46
Upside: +428.46%
Travere Therapeutics
May 2, 2025
Reiterates: Outperform
Price Target: $30
Current: $20.02
Upside: +49.85%
Edgewise Therapeutics
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $14.58
Upside: +194.92%
Tourmaline Bio
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $15.10
Upside: +184.77%
Gossamer Bio
Mar 14, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.11
Upside: +260.36%
Ovid Therapeutics
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.29
Upside: +934.13%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $19.61
Upside: +83.58%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $4.23
Upside: +561.94%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $17.30
Upside: +67.63%
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $6.57
Upside: -8.68%
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $115.71
Upside: +27.04%
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $35.11
Upside: +36.71%
Dec 13, 2024
Initiates: Outperform
Price Target: $16
Current: $2.76
Upside: +479.71%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.50
Upside: +702.68%
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $2.22
Upside: +80.18%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $2.12
Upside: +937.74%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $118.17
Upside: +73.48%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $35.02
Upside: +39.92%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.17
Upside: +120.82%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.62
Upside: +203.87%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $12.39
Upside: +238.98%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $9.36
Upside: +81.62%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $16.60
Upside: +86.75%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.29
Upside: +3,654.27%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.50
Upside: +42.86%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.86
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.13
Upside: +134.74%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $20.24
Upside: +633.70%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $6.45
Upside: +11,062.79%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $18.63
Upside: +1,402.95%